Journal article

Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort

K Tikk, D Sookthai, T Johnson, S Rinaldi, I Romieu, A Tjonneland, A Olsen, K Overvad, F Clavel-Chapelon, L Baglietto, H Boeing, A Trichopoulou, P Lagiou, D Trichopoulos, D Palli, V Pala, R Tumino, S Rosso, S Panico, A Agudo Show all

Annals of Oncology | OXFORD UNIV PRESS | Published : 2014


BACKGROUND: Experimental and epidemiological evidence suggests that prolactin might play a role in the etiology of breast cancer. We analyzed the relationship of prediagnostic circulating prolactin levels with the risk of breast cancer by menopausal status, use of postmenopausal hormone replacement therapy (HRT) at blood donation, and by estrogen and progesterone receptor status of the breast tumors. PATIENTS AND METHODS: Conditional logistic regression was used to analyze the data from a case-control study nested within the prospective European EPIC cohort, including 2250 invasive breast cancer and their matched control subjects. RESULTS: Statistically significant heterogeneity in the assoc..

View full abstract


Awarded by Spanish Ministry of Health

Awarded by Regional Government of Andalucia

Awarded by Regional Government of Asturias

Awarded by Regional Government of Basque Country

Awarded by Regional Government of Murcia

Awarded by ISCIII RETIC (Spain)

Awarded by Cancer Research UK

Awarded by Medical Research Council

Awarded by National Institute for Health Research

Funding Acknowledgements

We thank all the EPIC cohort participants. Furthermore, we thank Britta Lederer and Sigrid Henke for their work in conducting the immunoassays; Sabine Rohrmann, Jutta Schmitt, and Jutta Kneisel for their assistance during the collection of hormone receptor status data. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue contre le Cancer, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Norwegian Research Council, Norwegian Cancer Society, ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), The Spanish Ministry of Health (ISCIII RETICC RD06/0020/0091) and the Catalan Institute of Oncology, Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no 6236) and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK, Medical Research Council (UK).